Resources for Clinical Research Professionals

A: We're a technology platform, not just a vendor. Three things set us apart: (1) Our founder was Senior Marketing Manager at a leading patient recruitment platform before its nine-figure acquisition—we know the playbook; (2) We're published medical researchers (70+ citations) who understand clinical trials from the inside; (3) We've built an end-to-end platform covering recruitment through retention with real-time analytics.

A: Traditional methods rely on physician referrals and site databases—passive approaches. We actively reach patients through digital channels where they're already searching for treatment options, then pre-screen them before site referral so you get patients who are likely to qualify.

A: We've built a proprietary platform that includes: patient acquisition systems across social, search, and programmatic channels; a Patient Qualification Suite for pre-screening; a Site Portal for referral management; a Sponsor Analytics Dashboard for real-time visibility; and patient retention tools. All HIPAA-compliant.

A: Standard launch is 2-3 weeks from contract. This includes protocol review, campaign development, landing page creation, and coordinator training. For trials behind deadline, we can accelerate to 1-2 weeks.

A: We need: the study protocol (or at minimum the I/E criteria), site list with contact information, enrollment targets and timeline, any existing IRB-approved materials, and therapeutic area background if specialized.

A: We onboard sites to our portal, which gives them access to all patient referrals with complete screening notes. Sites can communicate with patients, schedule appointments, and update status. Training takes about 30 minutes.

A: Our Patient Qualification Suite contacts patients within minutes of sign-up. Trained coordinators conduct 15-20 minute pre-screening calls, verifying every eligibility criterion before site referral. Result: 75% reduction in screen failures.

A: We explain why they don't qualify for this particular study, answer their questions, and—if interested—add them to our database for future studies. Your sites never see unqualified referrals.

A: Absolutely—this is a core capability. Our founder is bilingual (English/Spanish), we run Spanish-language campaigns, employ native Spanish-speaking coordinators, and have community partnerships for underrepresented populations. We've increased Hispanic enrollment from 12% to 44% on cardiovascular trials.

A: We have targeted capabilities for Hispanic/Latino populations (our strongest specialty), African American/Black communities, Asian populations, elderly patients, rural communities, and other underrepresented groups.

A: Our digital approach works across any indication where patients search online for treatment options. We've recruited across oncology, cardiovascular, neurology/CNS, endocrinology, respiratory, mental health, dermatology, gastrointestinal, rare/orphan diseases, and vaccines.

A: Yes—we've recruited for rare diseases with as few as 3,000 diagnosed patients in the US. We use lookalike modeling, patient advocacy partnerships, and nationwide reach. Our rare disease case study shows 28 patients enrolled from an ultra-rare population in 5 months.

A: Our entire platform is built on HIPAA-compliant infrastructure: encrypted data storage and transmission, role-based access controls, complete audit trails, and regular security assessments. We execute Business Associate Agreements with all clients.

A: Sponsors access our real-time analytics dashboard showing: enrollment progress vs. targets, site-by-site performance, source/channel analytics, diversity metrics, and cost-per-enrollment. Weekly status updates and monthly detailed reports included.

A: Based on our track record: 94% faster enrollment timelines, 75% reduction in screen failure rates, 85% patient retention, and patient contact within minutes (not days). Specific results vary by therapeutic area and protocol complexity.